The Readout Loud

350 Avsnitt

1. 346: Zealand's obesity strategy and Immunovant's curious development plan

   Publicerades: 2025-03-20
2. 345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

   Publicerades: 2025-03-13
3. 344: Trump's FDA commissioner nominee takes the hot seat

   Publicerades: 2025-03-06
4. 343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

   Publicerades: 2025-02-27
5. 342: FDA cuts, zombie biotechs, and too much weight loss?

   Publicerades: 2025-02-20
6. 341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

   Publicerades: 2025-02-13
7. 340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

   Publicerades: 2025-02-06
8. 339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

   Publicerades: 2025-01-30
9. 338: Chinese biotechs, a WHO departure, and post-JPM thoughts

   Publicerades: 2025-01-23
10. 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

    Publicerades: 2025-01-15
11. 336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

    Publicerades: 2025-01-09
12. 335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

    Publicerades: 2024-12-19
13. 334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

    Publicerades: 2024-12-12
14. 333: An H5N1 bird flu update and talent scarcity in the radiopharma field

    Publicerades: 2024-12-05
15. 332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

    Publicerades: 2024-11-21
16. 331: AbbVie’s stumble, Amgen’s tumble and more election fallout

    Publicerades: 2024-11-14
17. 330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

    Publicerades: 2024-11-07
18. 329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

    Publicerades: 2024-10-31
19. 328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

    Publicerades: 2024-10-24
20. 327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

    Publicerades: 2024-10-17